Glancy Prongay & Murray LLP Announces Investigation on Behalf of Corcept Therapeutics Incorporated Investors
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Corcept Therapeutics Incorporated investors (“Corcept” or the “Company”) (NASDAQ: CORT) concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On January 25, 2019, Southern Investigative Reporting Foundation (SIRF) published a report alleging that Corcept paid doctors to prescribe its drug Korlym for off-label uses in 2016 – 2017. The report condemned the company for exploiting regulatory loopholes, charging patients an excessive price for its lone drug product, and touting evidence for the drug’s effectiveness that – according to SIRF – doesn’t exist. On this news, shares of Corcept fell $1.52, or 11%, to close at $12.29 on January 25, 2019, thereby injuring investors.
If you purchased Corcept stock, have information, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at 888-773-9244, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.